Table 11: Observed and Expected Malignancies at Different Follow-ups Followed From the Date of Primary Hip Replacement to the First Cancer, to Death, or to the End of 1989.

Cancer Site	Standardized Mortality Ratio (95% Confidence Interval)
	< 1 year	1 Year to < 2 years	By the Study End Point*
Upper gastrointestinal	2.07 (1.10–3.54)	0.59 (0.32–0.99)	0.88 (0.68–1.11)
Colorectal	1.94 (1.17–3.04)	0.56 (0.35–0.86)	0.95 (0.78–1.14)
Bile/liver/pancreas	2.28 (1.27–3.75)	0.44 (0.22–0.79)	0.94 (0.74–1.17)
Lung	1.75 (0.87–3.12)	0.52 (0.27–0.90)	0.76 (0.57–0.98)
Respiratory system, lung excluded	3.72 (1.01–9.51)	0.26 (0.01–1.43)	0.98 (0.51–1.71)
Breast	2.51 (1.64–3.68)	0.37 (0.20–0.61)	0.85 (0.69–1.03)
Female reproductive system	1.30 (0.56–2.57)	0.68 (0.38–1.13)	1.17 (0.93–1.46)
Male reproductive system	2.75 (1.68–4.25)	0.32 (0.14–0.60)	1.18 (0.97–1.42)
Kidney/urinary system	0.65 (0.18–1.65)	0.30 (0.12–0.63)	0.84 (0.65–1.08)
Malignant melanoma/skin	3.03 (1.51–5.42)	0.49 (0.20–1.00)	1.15 (0.87–1.50)
Eye/nervous system	1.01 (0.12–3.66)	0.83 (0.31–1.82)	0.88 (0.54–1.36)
Thyroid/endocrine gland	0.63 (0.02–3.50)	0.35 (0.04–1.26)	1.28 (0.81–1.92)
Bone/connective tissue	2.09 (.05–11.64)	0.00 (0.00–2.03)	0.85 (0.28–1.98)
Other/unspecified	0.99 (0.12–3.59)	0.13 (0.00–0.71)	1.08 (0.72–1.56)
Lymphoma/leukemia	2.66 (1.49–4.39)	0.42 (0.19–0.80)	0.89 (0.68–1.14)
All sites	2.02 (1.71–2.37)	0.46 (0.38–0.54)	0.96 (0.90–1.03)

^*From the date of primary hip replacement to the first cancer, to death, or to the end of 1989